Various methods have been used to detect IDH1/2 and FLT3 mutations in AML patients, such as direct sequencing, Restriction Fragment Length Polymorphism-Polymerase Chain Reaction (RFLP-PCR) or, recently, next generation sequencing (NGS) [14,15]. This evidence concerns the gene FLT3 and acute myeloid leukemia.